Association of Hepatitis C Virus With Breast Cancer

Completed

• Conditions: Breast Cancer; Hepatitis C

• Registration Number: NCT04090164
• Lead Sponsor: Mansoura University

Brief Summary

Hepatitis C viral infection is a major health problem in Egypt. The management of breast cancer patients is often complicated by the presence of associated HCV infection. This study aims at investigating the epidemiological association of the two conditions. It will also investigate the possible correlation with treatment outcome.

Detailed Description

Breast cancer is the most common cancer in adult Egyptian females. The world's highest prevalence of hepatitis C virus is found in Egypt. Several investigators examined the epidemiological association of HCV with breast cancer. Published literature reports conflicting results regarding the HCV association with breast cancer incidence. Population-based studies from HCV-endemic area demonstrated increased breast cancer incidence in HCV-positive women younger than 50 years. On the other hand, population studies from HCV-low prevalence regions failed to detect an association of the virus with breast cancer.

HCV seropositive patients constitute a large sector of oncology patients treated in Egyptian practice. HCV infection with or without clinically-significant liver disease impose several therapeutic, social and logistic problems. Recently, investigators from Mansoura University reported their findings among breast cancerpatients. According to these data, HCV-positive breast cancer patients had several markers of disease aggression such as large tumor size, high tumor grade and nodal infiltration. Moreover, HCV-NS4 (non-structural protein-4) blood levels positively correlated with the level of the known breast cancer marker CA15-3.

In the current study, the investigators will investigate the incidence of HCV seropositivity in breast cancer patients and an age-matched control group. The study also examines the association of HCV status on the patients' baseline characteristics such as tumor stage and grade and with patients' treatment plan and treatment outcome.

Specifically, the aims of the study are the following:

1. To test if HCV seropositivity is associated with breast cancer diagnosis in Egyptian population.

2. To test if HCV-positive patients harbour more aggressive breast tumors.

3. To test if HCV-positivity affects management decision in breast cancer patients.

4. To test if HCV-positive patients suffer more frequent adverse effects to breast cancer treatment.

5. To compare disease-free survival of HCV seropositive breast cancer patients vs. seronegative patients.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-01-14
• Study Start: 2019-09-01
• Study First Submitted QC: 2019-09-13
• Study First Posted: 2019-09-16
• Primary Completion: 2020-06-01
• Study Completion: 2020-06-01
• Results First Submitted: 2020-08-14
• Status Verified: 2020-09
• Results First Submitted QC: 2020-09-24
• Last Update Submitted: 2020-09-24
• Results First Posted: 2020-10-19
• Last Update Posted: 2020-10-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 650

Inclusion Criteria

• Biopsy-proven invasive breast cancer.

Read More

Exclusion Criteria

• Patients with unknown viral marker status.
• Patients who did not complete their management at OCMU.
• Patients with multiple cancer diagnoses.
• Patients with virus-unrelated hepatic pathology.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of HCV Seropositivity in Breast Cancer Patients.	This outcome will be assessed through study completion, an average of 6 months.	Percentage of patients with breast cancer with positive anti-HCV serological test.

Secondary Outcome Measures

Name	Time	Method
Disease-related Events	at the date of last patients' visit recorded on her file. Patients should be censored at least 12 months from the time of diagnosis.	The number of events related to breast cancer diagnosis. Disease-free survival (DFS) was calculated as the time from the date of breast cancer diagnosis to the date of last follow-up or the date of first breast cancer-related event. At the time of analysis, median survival has not been reached.

Trial Locations

Locations (1)

Mansoura University Oncology Center; 🇪🇬 Mansourah, DK, Egypt